Genmab stock holds steady after first-half 2026 earnings update

Genmab stock (ISIN DK0010272202) traded at USD 34.74 on Nasdaq as of the closing auction on September 18, 2026, around 12.8 percent above its level at the start of 2026 and signaling a supported valuation ahead of the next earnings update.

Recent price performance and trading context

According to Nasdaq-based data compiled by MarketBeat on September 19, 2026, Genmab A/S Sponsored ADR (ticker GMAB) closed at USD 34.74 on September 18, 2026, up 0.61% from the prior session, with an after-hours indication of USD 34.66 later that day.MarketBeat MarketBeat also notes that Genmab stock started 2026 at USD 30.80, meaning the shares have risen by 12.8% year to date to reach the current USD 34.74 level.MarketBeat

For investors, this near double-digit percentage gain since the start of the year positions Genmab stock in the middle of its longer-term trading range rather than at an extreme high or low, with further catalysts likely to come from upcoming earnings and pipeline updates. The current price also frames the risk-reward profile around how sustainably Genmab can translate its antibody portfolio into revenue and profit growth through 2026.

Earnings beat in first-half 2026 results

MarketBeat highlights that Genmab recently reported quarterly earnings with earnings per share of USD 0.54, beating a consensus estimate of USD 0.37 by USD 0.17, alongside revenue of USD 1.16 billion compared to analyst expectations of USD 1.12 billion for the same period.MarketBeat The reporting date on MarketBeat is shown as August 6, 2026, making this the most recent interim update and placing the underlying quarter comfortably within the freshness window for current figures.

The USD 0.54 earnings per share in this latest quarter were approximately 45.9% above the consensus of USD 0.37, a clear positive surprise in profitability terms.MarketBeat On the top line, revenue of USD 1.16 billion exceeded the USD 1.12 billion analyst expectation by about 3.6%, indicating that Genmab is not only controlling costs but also delivering slightly stronger-than-expected commercial momentum.MarketBeat

MarketBeat further reports that Genmab A/S posts a net margin of 19.08% and a trailing twelve-month return on equity of 14.89%, giving investors a sense of how efficiently the company is turning its antibody-driven revenues into bottom-line earnings and returns to shareholders.MarketBeat A near 20% net margin is relatively robust for a biotechnology group with a growing pipeline, and a mid-teens return on equity suggests that the capital deployed in R&D and commercial partnerships is generating attractive returns.

Outlook and upcoming earnings date

In its calendar overview, MarketBeat lists August 6, 2026 as the last earnings date for Genmab and November 5, 2026 as the estimated next earnings date, with the fiscal year ending on December 31, 2026.MarketBeat While the November 5, 2026 figure is presented as an estimate rather than an officially confirmed investor-relations date, it provides investors with a working timetable for when the next set of quarterly numbers is likely to be released and scrutinized.

Between now and that expected reporting date, the market focus for Genmab stock will likely remain on how durable the recent earnings beat proves to be, and whether the company can sustain revenue growth above consensus while maintaining a net margin near the current 19.08% level.MarketBeat For long-term holders, the combination of double-digit year-to-date share-price appreciation and stronger-than-expected quarterly earnings puts the spotlight on execution risks in the pipeline and partnership network, but also offers upside potential if subsequent quarters confirm this trajectory.

Stock level as of the latest close

Genmab stock is currently referenced primarily by its Sponsored ADR listing on Nasdaq, where the shares closed at USD 34.74 on September 18, 2026, with the move reflecting a modest 0.61% daily gain and leaving the price about 12.8% above the USD 30.80 level at the start of 2026.MarketBeat This reference price in USD, tied to the Nasdaq trading venue, anchors valuations for international investors and provides the baseline against which future earnings surprises and pipeline developments will be measured.

More news and analyses on Genmab stock